Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

532 ARTÍCULOS , VIENDO DEL 196 AL 210

Perspectives for New and More Efficient Multifunctional Ligands for Alzheimer's Disease Therapy

Zagórska A, Jaromin A.

Molecules. 2020 Jul 23;25(15):3337. doi: 10.3390/molecules25153337.

Cyclic Nucleotides Signaling and Phosphodiesterase Inhibition: Defying Alzheimer's Disease

Sharma VK, Singh TG, Singh S.

Curr Drug Targets. 2020;21(13):1371-1384. doi: 10.2174/1389450121666200727104728.

Privileged Pharmacophore of FDA Approved Drugs in Combination with Chalcone Framework: A New Hope for Alzheimer's Treatment

Mathew B.

Comb Chem High Throughput Screen. 2020;23(9):842-846. doi: 10.2174/1386207323999200728122627.

Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches

Kellar D, Craft S.

Lancet Neurol. 2020 Sep;19(9):758-766. doi: 10.1016/S1474-4422(20)30231-3. Epub 2020 Jul 27.

Transcription factor NRF2 as a promising therapeutic target for Alzheimer's disease

Qu Z, Sun J, Zhang W, Yu J, Zhuang C.

Free Radic Biol Med. 2020 Nov 1;159:87-102. doi: 10.1016/j.freeradbiomed.2020.06.028. Epub 2020 Jul 28.

Status and future directions of clinical trials in Alzheimer's disease

Plascencia-Villa G, Perry G.

Int Rev Neurobiol. 2020;154:3-50. doi: 10.1016/bs.irn.2020.03.022. Epub 2020 Jul 20.

P38α MAPK Signaling-A Robust Therapeutic Target for Rab5-Mediated Neurodegenerative Disease

Germann UA, Alam JJ.

Int J Mol Sci. 2020 Jul 31;21(15):5485. doi: 10.3390/ijms21155485.

Anti-amyloid-β protein agents for the treatment of Alzheimer's disease: an update on emerging drugs

Lozupone M, Solfrizzi V, D'Urso F, Di Gioia I, Sardone R, Dibello V, Stallone R, Liguori A, Ciritella C, Daniele A, Bellomo A, Seripa D, Panza F.

Expert Opin Emerg Drugs. 2020 Sep;25(3):319-335. doi: 10.1080/14728214.2020.1808621. Epub 2020 Aug 20.

The MMP-2/TIMP-2 System in Alzheimer Disease

Wang H, Huang L, Wu L, Lan J, Feng X, Li P, Peng Y.

CNS Neurol Disord Drug Targets. 2020;19(6):402-416. doi: 10.2174/1871527319666200812223007.

Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval

Tolar M, Abushakra S, Hey JA, Porsteinsson A, Sabbagh M.

Alzheimers Res Ther. 2020 Aug 12;12(1):95. doi: 10.1186/s13195-020-00663-w.

A Comparative Study on 5hmC Targeting Regulation of Neurons in AD Mice by Several Natural Compounds

Cao D, Jiang D, Zhou D, Yu H, Li J.

Biomed Res Int. 2020 Aug 5;2020:5016706. doi: 10.1155/2020/5016706. eCollection 2020.

Collapsin Response Mediator Proteins: Novel Targets for Alzheimer's Disease

Quach TT, Moutal A, Khanna R, Deems NP, Duchemin AM, Barrientos RM.

J Alzheimers Dis. 2020;77(3):949-960. doi: 10.3233/JAD-200721.

NLRP3 Inflammasome: A Potential Therapeutic Target in Fine Particulate Matter-Induced Neuroinflammation in Alzheimer's Disease

Shi JQ, Wang BR, Jiang T, Gao L, Zhang YD, Xu J.

J Alzheimers Dis. 2020;77(3):923-934. doi: 10.3233/JAD-200359.

Alzheimer's Disease and Specialized Pro-Resolving Lipid Mediators: Do MaR1, RvD1, and NPD1 Show Promise for Prevention and Treatment?

Miyazawa K, Fukunaga H, Tatewaki Y, Takano Y, Yamamoto S, Mutoh T, Taki Y.

Int J Mol Sci. 2020 Aug 12;21(16):5783. doi: 10.3390/ijms21165783.

The potential role of nanoyttria in alleviating oxidative stress biomarkers: Implications for Alzheimer's disease therapy

Tang KS.

Life Sci. 2020 Oct 15;259:118287. doi: 10.1016/j.lfs.2020.118287. Epub 2020 Aug 16.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias